Related Experiment Videos
Acetylation phenotype in rheumatoid arthritis
Scandinavian Journal of Rheumatology
|January 1, 1978
Summary
The study examined isoniazid acetylation rates in rheumatoid arthritis (RA) patients and controls. No significant difference was found, though rapid acetylator prevalence was higher than in the general Finnish population.
Area of Science:
- Pharmacogenetics
- Rheumatology
- Drug Metabolism
Background:
- Rheumatoid arthritis (RA) is an autoimmune disease.
- Isoniazid (INH) acetylation is a genetically determined metabolic pathway.
- Understanding INH acetylation in RA may impact treatment.
Purpose of the Study:
- To investigate the acetylation rate of isoniazid (INH) in patients with rheumatoid arthritis (RA).
- To compare INH acetylation phenotypes between RA patients and cardiac arrhythmia controls.
- To explore correlations between acetylation phenotype and RA clinical parameters or gold salt sensitivity.
Main Methods:
- Studied 39 RA patients and 20 cardiac arrhythmia controls.
- Assessed isoniazid (INH) acetylation rates.
- Compared observed acetylation phenotypes with population data.
Main Results:
- No statistically significant difference in INH acetylation rates between RA patients and controls.
- Higher percentages of rapid acetylators (59% RA, 55% controls) than the Finnish population (44%).
- No correlation found between polymorphic acetylation phenotype and RA clinical parameters or gold salt sensitivity.
Conclusions:
- The polymorphic acetylation of isoniazid does not appear to differ significantly between RA patients and controls.
- Rapid isoniazid acetylation is prevalent in the studied Finnish RA and control cohorts.
- Acetylation phenotype is not associated with RA disease activity or response to gold therapy.